
==== Front
J Antimicrob Chemother
J Antimicrob Chemother
jac
Journal of Antimicrobial Chemotherapy
0305-7453
1460-2091
Oxford University Press UK

10.1093/jac/dkae285
dkae285
Supplement Paper
AcademicSubjects/MED00740
AcademicSubjects/MED00290
AcademicSubjects/MED00230
JAC Supplement: ‘faster ID and AST revolution: how to improve antibiotic use in the critically ill’
https://orcid.org/0000-0002-8443-314X
Slavin Monica Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia

Johnson Alan Journal of Antimicrobial Chemotherapy, Birmingham B1 3NJ, UK

Corresponding author. E-mail: Monica.slavin@petermac.org
9 2024
19 9 2024
19 9 2024
79 Suppl 1 Faster ID and AST revolution: How to Improve Antibiotic Use in the Critically Ill i1i1
© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

bioMérieux 10.13039/501100022110
==== Body
pmcPreface

Rapid determination of the aetiology of an infection and the antimicrobial susceptibility of the causative pathogen is critical for guiding timely initiation of effective therapy. In a series of six articles in this JAC Supplement the authors describe their experience of the advantages and limitations of various diagnostic laboratory methods and the challenges around translating rapidly generated test results into improved clinical outcomes for patients with infections. Topics covered include: the validation of a short-incubation method for rapid identification of bacteria from blood culture using MALDI-TOF MS; the potential of VITEK® REVEALTM to rapidly generate antimicrobial susceptibility test results; issues around the communication of rapid diagnostic test results to appropriate clinical personnel and the implementation of real-time antimicrobial stewardship activity; potential barriers faced by clinical microbiology laboratories to implementation of rapid identification and antimicrobial susceptibility testing; and a review of metrics that have been used to assess the impact of rapid susceptibility testing on clinical management and patient outcomes, together with factors potentially affecting these metrics.

It is hoped that this Supplement will provide a valuable resource for technical staff, clinicians, pharmacists and others looking to improve laboratory support for management of infected patients and improved antimicrobial stewardship practice.

Funding

This paper was published as part of a supplement financially supported by bioMérieux.

Transparency declarations

None to declare.
